- Sutimlimab - Wikipedia
Sutimlimab, sold under the brand name Enjaymo, is a monoclonal antibody that is used to treat adults with cold agglutinin disease (CAD) [1][3][4] It is given by intravenous infusion [1] Sutimlimab prevents complement-enhanced activation of autoimmune human B cells in vitro [5]
- Sutimlimab in Cold Agglutinin Disease - The New England Journal of Medicine
Sutimlimab (formerly BIVV009) is a first-in-class, humanized monoclonal antibody designed to target C1s, which is responsible for activating the classic complement pathway
- Sutimlimab Uses, Side Effects Warnings - Drugs. com
What is sutimlimab? Sutimlimab is used to treat the breakdown of red blood cells (hemolysis) in adults with cold agglutinin disease (CAD) Sutimlimab may also be used for purposes not listed in this medication guide
- Enjaymo (sutimlimab): Uses, Side Effects, Dosage Reviews - GoodRx
Enjaymo (sutimlimab or sutimlimab-jome) is a newly-approved medication used to lower the need for blood transfusions in adults with a rare form of anemia called cold agglutinin disease (CAD) It's given as an infusion into the veins by a healthcare provider
- Sutimlimab - Memorial Sloan Kettering Cancer Center
Stay away from people with infections, colds, or flu This drug raises the risk of severe infections, especially meningococcal, Haemophilus influenzae, and Streptococcus pneumoniae infections Life-threatening and deadly infections have happened in people treated with this type of drug
- FDA Approves Enjaymo® after pivotal study results | Sanofi
The U S Food and Drug Administration (FDA) has approved Enjaymo™ (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD)
- Sutimlimab in Cold Agglutinin Disease
In patients with cold agglutinin disease who received sutimlimab, selective up stream inhibition of activity in the classic complement pathway rapidly halted hemolysis, increased hemoglobin
- Enjaymo (sutimlimab) dosing, indications, interactions, adverse effects . . .
Indicated for treatment of hemolysis in adults with cold agglutinin disease (CAD) 39 to <75 kg: 6,500 mg IV weekly for first 2 weeks, then q2Weeks thereafter ≥75 kg: 7,500 mg IV
|